Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo BMT for Primary Immunodeficiencies
NCT02579967Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2015
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 2, open-label trial in primary immunodeficiency (PI) (6 arms), sponsored by National Cancer Institute. Primary endpoints: Acute Graft-Versus-Host Disease-Free, Graft Failure-Free Survival at 180 days and Shortest Duration of Mycophenolate Mofetil Safely Administered. Started Nov 2015; status: recruiting.
02
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT02579967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579967.